The goal of commercialization is to get the products of research out into the world for the public good. Asset Development funding helps develop early-stage technologies and make them more attractive for market adoption. The program is generating opportunities – and results.

UA Associate Vice President Bruce Wright received the COO/Leadership Equivalent Award for a non-profit organization during the 2017 Executive Excellence Award presented by Tucson Local Media and Inside Tucson Business.

Download the FY2017 Annual Report and review our progress against our 2020 vision and our metrics, the achievements of Tech Parks Arizona, and the big picture of the growth of the culture of commercialization throughout the University of Arizona ecosystem.

At a time when opioid addiction represents a major public health crisis, researchers in the UA College of Medicine – Tucson have invented a new class of non-opioid drug candidates to treat pain. The University has licensed the compounds to startup Regulonix.

The UA has licensed a drug that aims to shorten the lives of cancer cells to startup Reglagene. The technology, invented at the UA College of Pharmacy and the BIO5 Institute by Laurence Hurley, PhD, and Vijay Gokhale, PhD, has been shown to be effective in inducing cancer cells to grow old and die.

UA College of Medicine – Tucson Professor Meredith Hay, PhD, and her colleagues started ProNeurogen to commercialize their inventions in neuroscience and cardiovascular neurophysiology. The UA has been awarded two patents for their approach to treating memory loss and cognitive impairment.